Literature DB >> 10680925

Consequences to hearing during the conservative management of vestibular schwannomas.

R M Walsh1, A P Bath, M L Bance, A Keller, J A Rutka.   

Abstract

OBJECTIVE: To estimate the risk of loss of serviceable hearing during the conservative management of vestibular schwannomas. STUDY
DESIGN: Retrospective case review.
METHODS: Twenty-five patients with a radiological diagnosis of unilateral vestibular schwannoma were managed conservatively for a mean duration of 43.8 months (range, 12-194 mo). The pure-tone average (PTA) (0.5, 1, 2, and 3 kHz) and speech discrimination scores (SDS) were measured at regular intervals throughout the entire duration of follow-up. Serviceable hearing was defined using two criteria: 70% SDS/30 dB PTA (the 70/30 rule) and 50% SDS/50 dB PTA (the 50/50 rule). The size and growth rate of tumors were determined according to the American Academy of Otolaryngology-Head and Neck Surgery guidelines (1995). Intervention was recommended if there was evidence of continuous or rapid radiological tumor growth, and/or increasing symptoms or signs suggestive of tumor growth.
RESULTS: The risk of loss of serviceable hearing for the total group was 43% using the 70/30 rule and 42% using the 50/50 rule. Tumor growth was considered significant (> 1 mm) in 8 tumors (32%) and nonsignificant in 17 (68%). The risk of loss of serviceable hearing for the tumor-growth group was 67% using the 70/30 rule and 80% using the 50/50 rule. In contrast, the risk of loss of serviceable hearing for the no tumor-growth group was 25% using the 70/30 rule and 14% using the 50/50 rule. No audiological factors predictive of tumor growth were identified.
CONCLUSIONS: There is a significant risk of loss of serviceable hearing during the conservative management of vestibular schwannomas. This risk appears to be greater in tumors that demonstrate significant growth.

Entities:  

Mesh:

Year:  2000        PMID: 10680925     DOI: 10.1097/00005537-200002010-00012

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  14 in total

1.  Lipoma of the internal auditory canal: MR findings.

Authors:  J C Méndez; G Saucedo; P Ruiz; A Vega; L Nombela
Journal:  Eur Radiol       Date:  2001-11-23       Impact factor: 5.315

2.  Determining benchmarks in hearing preservation surgery for vestibular schwannoma.

Authors:  Michael B Gluth; John D Day; John L Dornhoffer
Journal:  J Neurol Surg B Skull Base       Date:  2012-08

3.  Self reported hearing loss among elderly malaysians.

Authors:  Ak Rosdina; M Leelavathi; A Zaitun; Vkm Lee; Mn Azimah; Sh Majmin; Ka Mohd
Journal:  Malays Fam Physician       Date:  2010-08-31

4.  In reference to "The transotic approach for vestibular schwannoma: indications and results".

Authors:  Kiruba Shankar Manoharan; Alok Thakar; Suresh C Sharma
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-08-04       Impact factor: 2.503

5.  Long-term hearing preservation after microsurgical excision of vestibular schwannoma.

Authors:  Erika Ann Woodson; Ryan Douglas Dempewolf; Samuel Paul Gubbels; Aaron Thomas Porter; Jacob Jay Oleson; Marlan Rex Hansen; Bruce Jay Gantz
Journal:  Otol Neurotol       Date:  2010-09       Impact factor: 2.311

6.  Long term results of primary radiosurgery for vestibular schwannomas.

Authors:  Stephen Johnson; Hideyuki Kano; Andrew Faramand; Matthew Pease; Aya Nakamura; Mohab Hassib; David Spencer; Nathaniel Sisterson; Amir H Faraji; Yoshio Arai; Edward Monaco; Ajay Niranjan; John C Flickinger; L Dade Lunsford
Journal:  J Neurooncol       Date:  2019-09-18       Impact factor: 4.130

7.  Expectant management of vestibular schwannoma: a retrospective multivariate analysis of tumor growth and outcome.

Authors:  Mark Hughes; Christopher Skilbeck; Shakeel Saeed; Robert Bradford
Journal:  Skull Base       Date:  2011-09

8.  Progress of hearing loss in neurofibromatosis type 2: implications for future management.

Authors:  Georgios Kontorinis; Jaya Nichani; Simon R Freeman; Scott A Rutherford; Samantha Mills; Andrew T King; Deborah Mawman; Sue Huson; Martin O'Driscoll; D Gareth Evans; Simon K W Lloyd
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10-08       Impact factor: 2.503

Review 9.  Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.

Authors:  Scott R Plotkin; Chris Halpin; Jaishri O Blakeley; William H Slattery; D Bradley Welling; Susan M Chang; Jay S Loeffler; Gordon J Harris; A Gregory Sorensen; Michael J McKenna; Fred G Barker
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

10.  Systematic Review of Hearing Preservation After Radiotherapy for Vestibular Schwannoma.

Authors:  Adam R Coughlin; Tyler J Willman; Samuel P Gubbels
Journal:  Otol Neurotol       Date:  2018-03       Impact factor: 2.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.